Interestingly, Yan et al. demonstrated that UNG depletion resensitizes p53-mutant and p53-deficient cancer cells to 5-FU, suggesting that in these cells, UNG is an attractive therapeutic target to enhance the response to TS inhibitors but not in wt-p53 cells, where the apoptosis pathway induced by 5-FU is independent of UNG status [114]. The gene discussed is TP53; the disease is cancer.